Verdiva launches with $410M series A to fund weekly-dosed weight loss drug trials, pipeline growth Bayer makes hot flash splash, hitting phase 3 breast cancer goal to steal march on Astellas Lonza's Synaffix adds Boehringer to its constellation of partners with $1.3B ADC tech pact Velia Therapeutics winds down but stays loyal to 'therapeutic potential of microproteins' Lilly crafts deal for up to 5 new ALS antibodies with UK biotech Alchemab Scribe slims down workforce as it readies cardiometabolic genetic meds for clinic MaaT's phase 3 GvHD trial hits goal, teeing up microbiome filing if cash crunch clears Astellas calls it quits on early-stage lymphoma CAR-T following pipeline review Cash-strapped Windtree's new strategy involves buying biotechs with FDA-approved products Fierce Biotech Fundraising Tracker '25: Verdiva launches with $410M; A2 adds $80M After rejection, Vanda CEO pens searing letter to FDA commissioner about ‘disturbing pattern of conduct’ Climb Bio ascends from Eliem legacy with $9M upfront deal for preclinical IgA antibody | 